Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest
J Dermatolog Treat. 2024 Dec;35(1):2340107. doi: 10.1080/09546634.2024.2340107. Epub 2024 Apr 18.ABSTRACTBrodalumab, a human monoclonal antibody that targets interleukin-17 receptor A (IL-17RA), is approved in the US and EU for treatment of adults with moderate-to-severe plaque psoriasis. Although brodalumab has demonstrated efficacy and safety vs placebo in clinical trials of patients with psoriasis and psoriatic arthritis (PsA), real-world evidence is needed to evaluate long-term effectiveness and safety of brodalumab in routine care. This interim analysis of the German Psoriasis Registry PsoBest examined patient profile...
Source: Journal of Dermatological Treatment - April 18, 2024 Category: Dermatology Authors: Lisa Schaeffer Nesrine Ben-Anaya Christina Sorbe Stephan Jeff Rustenbach Ulrich Mrowietz Matthias Augustin Source Type: research
Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials
J Dermatolog Treat. 2024 Dec;35(1):2342383. doi: 10.1080/09546634.2024.2342383. Epub 2024 Apr 18.ABSTRACTIn the KEEPsAKE 1 (NCT03675308) and KEEPsAKE 2 (NCT03671148) phase 3 trials, risankizumab demonstrated greater efficacy compared with placebo in patients with active psoriatic arthritis (PsA). This post hoc integrated analysis evaluated achieving the following efficacy outcomes at weeks 24 and 52 by baseline demographics and clinical characteristics: ≥20%/50%/70% improvement in American College of Rheumatology response criteria (ACR20/50/70), ≥90% improvement in Psoriasis Area and Severity Index, minimal disease act...
Source: Journal of Dermatological Treatment - April 18, 2024 Category: Dermatology Authors: Joseph F Merola April Armstrong Saakshi Khattri So Yeon Paek Byron Padilla Cuiyong Yue Huzefa Photowala Blair Kaplan Lars Erik Kristensen Source Type: research
Use of risk chart algorithms for the identification of psoriatic arthritis patients at high risk for cardiovascular disease: findings derived from the project CARMA cohort after a 7.5-year follow-up period
CONCLUSIONS: Risk chart algorithms are very useful for discriminating PsA at low and high CV risk. An integrated model featuring QRISK3 and SCORE2 yielded the optimal synergy of QRISK3's discrimination ability and SCORE2's calibration accuracy.PMID:38631846 | DOI:10.1136/rmdopen-2024-004207 (Source: Atherosclerosis)
Source: Atherosclerosis - April 17, 2024 Category: Cardiology Authors: Jessica Polo Y La Borda Santos Casta ñeda Elena Heras-Recuero Fernando S ánchez-Alonso Zulema Plaza Carmen Garc ía Gómez Ivan Ferraz-Amaro Jes ús Tomás Sanchez-Costa Olga Carmen S ánchez-González Ana Isabel Turri ón-Nieves Ana Perez-Alcal á Caro Source Type: research
Use of risk chart algorithms for the identification of psoriatic arthritis patients at high risk for cardiovascular disease: findings derived from the project CARMA cohort after a 7.5-year follow-up period
CONCLUSIONS: Risk chart algorithms are very useful for discriminating PsA at low and high CV risk. An integrated model featuring QRISK3 and SCORE2 yielded the optimal synergy of QRISK3's discrimination ability and SCORE2's calibration accuracy.PMID:38631846 | DOI:10.1136/rmdopen-2024-004207 (Source: Atherosclerosis)
Source: Atherosclerosis - April 17, 2024 Category: Cardiology Authors: Jessica Polo Y La Borda Santos Casta ñeda Elena Heras-Recuero Fernando S ánchez-Alonso Zulema Plaza Carmen Garc ía Gómez Ivan Ferraz-Amaro Jes ús Tomás Sanchez-Costa Olga Carmen S ánchez-González Ana Isabel Turri ón-Nieves Ana Perez-Alcal á Caro Source Type: research
Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis
ConclusionsThis meta-analysis showed that the investigated IL-17 and IL-23 inhibitors had high drug survival rates, with highest rates for guselkumab and risankizumab drug survival. We showed that effect modifiers such as biologic naivety, and the source of data used (registry/electronic health record data vs pharmacy/claims databases) is relevant when interpreting drug survival studies. (Source: Drugs)
Source: Drugs - April 17, 2024 Category: Drugs & Pharmacology Source Type: research
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis
ConclusionIn biologic-na ïve patients with active PsA treated with guselkumab, achieving ER or DR was associated with durable improvements in selected PROs, including those of high importance to patients.Trial registrationClinicalTrials.gov (https://clinicaltrials.gov) NCT03158285; Registered: May 16, 2017.Key Points•At week 100, 65% and 76% of guselkumab-treated patients achieved enthesitis and dactylitis resolution (ER/DR).•Achieving ER was associated with achieving DR and vice versa through the end of study.•Achieving ER or DR was associated with durable and meaningful improvements in selected patient-reported ou...
Source: Clinical Rheumatology - April 16, 2024 Category: Rheumatology Source Type: research
Efficacy and safety of tofacitinib for chronic plaque psoriasis and psoriatic arthritis: a systematic review and meta-analysis of randomized controlled trials
ConclusionsA comprehensive analysis revealed that tofacitinib has a positive effect on addressing skin and joint symptoms, as well as improving the quality of life for patients with chronic plaque psoriasis and psoriatic arthritis (PsA). However, the safety of the drug ’s long-term usage even requires further validation.Key Points• In 6 analyses involving a total of 1393 patients, tofacitinib exhibits positive effect on the treatment of both chronic plaque psoriasis and psoriatic arthritis (PsA).• Although dose-based subgroup analyses have demonstrated effectiveness. Some studies indicate that the 5-mg dose (twice da...
Source: Clinical Rheumatology - April 16, 2024 Category: Rheumatology Source Type: research
American College of Rheumatology (ACR) and Food and Drug Administration (FDA) Summit: Summary of the Meeting May 17 ‐18, 2022
On May 17-18, 2022, the ACR and the FDA co-sponsored a public meeting to address topics of mutual interest and importance in assessing long-term safety and clinical efficacy, as well as novel approaches to clinical trials in rheumatoid arthritis (RA) and psoriatic arthritis (PsA). During the two-day consensus-building summit, rheumatologists, other health care professionals, and FDA staff provided a broad perspective on current clinical development challenges and potential approaches to address them. Key takeaways are summarized in this document, including issues related to innovative clinical trial designs, use of novel o...
Source: Arthritis and Rheumatology - April 16, 2024 Category: Rheumatology Authors: Jonathan Kay,
Nikolay P. Nikolov,
Michael H. Weisman,
for the
American College of Rheumatology Committee on Research Tags: Special Article Source Type: research
Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies
ConclusionsIn this challenging sub-population of US patients with PsA, secukinumab provided rapid improvements in disease activity and QoL. Patients with PsA and active psoriasis might benefit more from secukinumab 300 mg than 150 mg. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - April 16, 2024 Category: Rheumatology Source Type: research
Efficacy and safety of tofacitinib for chronic plaque psoriasis and psoriatic arthritis: a systematic review and meta-analysis of randomized controlled trials
ConclusionsA comprehensive analysis revealed that tofacitinib has a positive effect on addressing skin and joint symptoms, as well as improving the quality of life for patients with chronic plaque psoriasis and psoriatic arthritis (PsA). However, the safety of the drug ’s long-term usage even requires further validation.Key Points• In 6 analyses involving a total of 1393 patients, tofacitinib exhibits positive effect on the treatment of both chronic plaque psoriasis and psoriatic arthritis (PsA).• Although dose-based subgroup analyses have demonstrated effectiveness. Some studies indicate that the 5-mg dose (twice da...
Source: Clinical Rheumatology - April 15, 2024 Category: Rheumatology Source Type: research
When Should I Get My Next COVID Vaccine? Data from the SUrveillance of responses to COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)study
CONCLUSION: Ours is the first pan-Canadian IMID assessment of how vaccine history and other factors affect serologic COVID-19 vaccine responses. These findings may help individuals personalize vaccination decisions, including consideration of additional vaccination when >6 months has elapsed since last COVID vaccination/infection.PMID:38621797 | DOI:10.3899/jrheum.2023-1214 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 15, 2024 Category: Rheumatology Authors: Dawn M E Bowdish Vinod Chandran Carol A Hitchon Gilaad G Kaplan J Antonio Avina-Zubieta Paul R Fortin Maggie J Larch é Gilles Boire Anne-Claude Gingras Roya M Dayam Ines Colmegna Luck Lukusa Jennifer L F Lee Dawn P Richards Daniel Pereira Tania H Watts M Source Type: research
When Should I Get My Next COVID Vaccine? Data from the SUrveillance of responses to COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)study
CONCLUSION: Ours is the first pan-Canadian IMID assessment of how vaccine history and other factors affect serologic COVID-19 vaccine responses. These findings may help individuals personalize vaccination decisions, including consideration of additional vaccination when >6 months has elapsed since last COVID vaccination/infection.PMID:38621797 | DOI:10.3899/jrheum.2023-1214 (Source: J Rheumatol)
Source: J Rheumatol - April 15, 2024 Category: Rheumatology Authors: Dawn M E Bowdish Vinod Chandran Carol A Hitchon Gilaad G Kaplan J Antonio Avina-Zubieta Paul R Fortin Maggie J Larch é Gilles Boire Anne-Claude Gingras Roya M Dayam Ines Colmegna Luck Lukusa Jennifer L F Lee Dawn P Richards Daniel Pereira Tania H Watts M Source Type: research
When Should I Get My Next COVID Vaccine? Data from the SUrveillance of responses to COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)study
CONCLUSION: Ours is the first pan-Canadian IMID assessment of how vaccine history and other factors affect serologic COVID-19 vaccine responses. These findings may help individuals personalize vaccination decisions, including consideration of additional vaccination when >6 months has elapsed since last COVID vaccination/infection.PMID:38621797 | DOI:10.3899/jrheum.2023-1214 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 15, 2024 Category: Rheumatology Authors: Dawn M E Bowdish Vinod Chandran Carol A Hitchon Gilaad G Kaplan J Antonio Avina-Zubieta Paul R Fortin Maggie J Larch é Gilles Boire Anne-Claude Gingras Roya M Dayam Ines Colmegna Luck Lukusa Jennifer L F Lee Dawn P Richards Daniel Pereira Tania H Watts M Source Type: research
When Should I Get My Next COVID Vaccine? Data from the SUrveillance of responses to COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)study
CONCLUSION: Ours is the first pan-Canadian IMID assessment of how vaccine history and other factors affect serologic COVID-19 vaccine responses. These findings may help individuals personalize vaccination decisions, including consideration of additional vaccination when >6 months has elapsed since last COVID vaccination/infection.PMID:38621797 | DOI:10.3899/jrheum.2023-1214 (Source: J Rheumatol)
Source: J Rheumatol - April 15, 2024 Category: Rheumatology Authors: Dawn M E Bowdish Vinod Chandran Carol A Hitchon Gilaad G Kaplan J Antonio Avina-Zubieta Paul R Fortin Maggie J Larch é Gilles Boire Anne-Claude Gingras Roya M Dayam Ines Colmegna Luck Lukusa Jennifer L F Lee Dawn P Richards Daniel Pereira Tania H Watts M Source Type: research
When Should I Get My Next COVID Vaccine? Data from the SUrveillance of responses to COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)study
CONCLUSION: Ours is the first pan-Canadian IMID assessment of how vaccine history and other factors affect serologic COVID-19 vaccine responses. These findings may help individuals personalize vaccination decisions, including consideration of additional vaccination when >6 months has elapsed since last COVID vaccination/infection.PMID:38621797 | DOI:10.3899/jrheum.2023-1214 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 15, 2024 Category: Rheumatology Authors: Dawn M E Bowdish Vinod Chandran Carol A Hitchon Gilaad G Kaplan J Antonio Avina-Zubieta Paul R Fortin Maggie J Larch é Gilles Boire Anne-Claude Gingras Roya M Dayam Ines Colmegna Luck Lukusa Jennifer L F Lee Dawn P Richards Daniel Pereira Tania H Watts M Source Type: research
